A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.
Thromb Res
; 133(2): 190-5, 2014 Feb.
Article
em En
| MEDLINE
| ID: mdl-24368019
Palavras-chave
ADP; Biomarkers; CD40 ligand; CD40L; EDTA; GPIIbIIIa; P2Y(12) receptor antagonist; PD; PK; Platelets; Prasugrel; RBCs; SCD; SD; Sickle cell disease; TF; TXB(2); VOC; adenosine diphosphate; ethylenediaminetetraacetic acid; glycoprotein IIb-IIIa; pharmacodynamics; pharmacokinetics; red blood cells; sickle cell disease; standard deviation; thromboxane B(2); tissue factor; vaso-occlusive crisis
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piperazinas
/
Tiofenos
/
Coagulação Sanguínea
/
Plaquetas
/
Ativação Plaquetária
/
Antagonistas do Receptor Purinérgico P2Y
/
Anemia Falciforme
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Thromb Res
Ano de publicação:
2014
Tipo de documento:
Article